Telo Genomics

Telo Genomics FCF Yield

The Free Cash Flow Yield of Telo Genomics (TELO.V) as of Oct 16, 2026 is -46.44 %. In the previous year, Free Cash Flow Yield was -49.07 % — a change of -5.37% (higher).

FCF Yield

-46.44 %

YoY

-5.37%

Last updated:

Free Cash Flow Yield of Telo Genomics is 2025 -46.44 % . Free Cash Flow Yield of Telo Genomics was 2024 -49.07 % . It decreases by -5.37% higher compared to the previous year.

The Telo Genomics FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-64.32 CAD
Jan 1, 2019
-6.71 CAD
Jan 1, 2020
-22.47 CAD
Jan 1, 2021
-22.18 CAD
Jan 1, 2022
-36.25 CAD
Jan 1, 2023
-53.74 CAD
Jan 1, 2024
-49.07 CAD
Jan 1, 2025
-46.44 CAD
The Telo Genomics FCF Yield history
YEARFCF YieldYoY
-46.44 %-5.37%
-49.07 %-8.68%
-53.74 %+48.26%
-36.25 %+63.41%
-22.18 %-1.28%
-22.47 %+234.64%
-6.71 %-89.56%
-64.32 %-61.45%
-166.83 %+3,652.81%
-4.45 %+100.98%
-2.21 %+213.13%
-0.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telo Genomics Stock analysis

What does Telo Genomics do? Telo Genomics Corp, a biotechnology company based in Toronto, Ontario, focuses on developing and commercializing technological products aimed at personalizing treatment plans for patients with specific conditions. The company, which went public on February 15, 2012, is engaged in the development of predictive diagnostic tools. Its lead product, TeloView SMM, is a high-complexity molecular assay designed for clinical use. TeloView SMM provides physicians with information to guide treatment decisions for patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, the assay identifies high-risk patients who may benefit from earlier intervention and distinguishes them from low-risk patients with a more stable disease course who do not require immediate treatment. Telo Genomics Corp operates through its wholly owned subsidiary, Telo Genomics Holdings Corp., which is developing diagnostic and prognostic products for diseases exhibiting genomic instability. The company's website is www.telodx.com. Telo Genomics Corp is listed on the Canadian market under the ticker TELO.V with ISIN CA87975M2085. Telo Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telo Genomics stock

Free Cash Flow Yield of Telo Genomics is -46.44 % in 2025.

Free Cash Flow Yield of Telo Genomics changed from -49.07 % to -46.44 %, representing a -5.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Telo Genomics since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Telo Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Telo Genomics

All Key Metrics — Telo Genomics